Key Highlights
- PRM shares climbed around 7% with no new company announcement dated to the session identified.
- Revenue fell from £7.78 million in 2022 to £3.76 million in 2025, alongside an adjusted EBITDA loss of £1.72 million for the last full year.
- Management flagged 'good progress' in order levels at the May 2026 AGM, with improving TMT and reagent sales during the first half.
- The company secured a significant new clinical contract for its chemoproteomics platform in late June 2026.
A Specialist in Protein Biomarkers, Still Finding Its Footing
Proteome Sciences offers contract proteomics services that support drug discovery, development and biomarker identification for pharmaceutical and academic clients, using proprietary techniques such as its TMT (tandem mass tag) reagent technology to analyse proteins in tissue, cell and body-fluid samples. It's a specialist, niche Business serving a scientific research market that has been squeezed in recent years by tighter US academic and NIH funding.
That funding squeeze showed up clearly in the company's financial trajectory: Revenue fell from £7.78 million in 2022 to £3.76 million in 2025, and the company reported an adjusted EBITDA loss of £1.72 million for its last full financial year. The Market Capitalisation now sits at only around £5.4 million, reflecting the scale of the challenge the business has faced.
Signs of a Gradual Recovery
More recently, management commentary has turned more constructive. At the company's AGM in May 2026, chairman Christopher Pearce said 'good progress is being made in order levels' in the services business, and pointed to improving TMT and reagent sales materialising during the first half of the year as the earlier funding constraints began to ease.
In late June 2026, Proteome Sciences confirmed it had secured a significant new clinical contract for its chemoproteomics platform, a development the company framed as validation of its technology ahead of further commercial opportunities. That win remains the most recent substantive catalyst on the public record, some two months before the Volatility highlighted around 4 September.
Why a Single Session Move Should Be Treated With Caution
With a market capitalisation of only around £5 million and a share price still roughly 65% below its 52-week high, Proteome Sciences is exactly the kind of stock where relatively small trades can generate large percentage swings without any accompanying news. That dynamic makes it difficult to attribute the day's gain to a specific event.
Nonetheless, the broader direction of travel described by management — improving order levels, a return of academic and NIH-funded work, and a new clinical contract win — provides some underlying context for renewed attention, even without a fresh announcement dated to the session itself. The company also appointed a new nominated adviser and broker earlier in the year, a change that sometimes precedes greater engagement as a small company works to raise its profile in the market.
Conclusion
Proteome Sciences' 7% jump can't be pinned to any specific news event, and in a stock this small and thinly traded, that's not unusual. What's more interesting is the gradual improvement in the underlying narrative — better order levels, easing funding constraints, and a new chemoproteomics contract win. Whether that translates into a sustained recovery will depend on consecutive positive updates rather than any single day's trading move.


_11_18_2026_11_51_48_599283.jpg)



Please wait processing your request...